9 cancer-related gene sets were demonstrated to be significantly enriched in the high-risk patient group (Nominal p-value < 0.05, FDR <0.25), including mTORC1 signaling, MYC targets v1, MYC targets v2, G2M checkpoint, E2F targets, mitotic spindle, glycolysis, DNA repair, and unfolded protein response (Figure 6). This evidence concerns the gene TRGV9 and cancer.